Literature DB >> 10441994

[A case of nephrotic syndrome with diabetes mellitus and primary aldosteronism].

H Mani1, K Takeda, M Kiyama, S Morimoto, T Nakata, S Sasaki, M Nakagawa.   

Abstract

A 65-year-old man had been followed by a family doctor for the treatment of hypertension and chronic hepatitis (type C) for about 20 years. Although he was pointed out to have impaired glucose tolerance and primary aldosteronism in 1995, he refused an adrenal tumor operation. He was admitted to our hospital on December, 1997 for further evaluation of general malaise, pitting edema of the legs, and positive urinary protein. A diagnosis of nephrotic syndrome was made on admission and a renal biopsy was performed. Histological findings indicated that he was at the early phase of diabetic nephropathy and hypertensive renal sclerosis. It is commonly believed that diabetic nephropathy develops after ten years of diabetic history and under poor control conditions. The diabetic history of this patient was only several years and the disease was under good control. In contrast to blood glucose, hypertension was not well-controlled with any antihypertensive drug, because he had a primary aldosteronism. Unfortunately, he could not take a spironolactone because of side effects. After removal of his adrenal tumor, his blood pressure was normalized gradually, and concomitantly his urinary protein was reduced and plasma protein and albumin were restored. Hypokalemia also disappeared. These findings suggest that uncontrolled hypertension may have accelerated the condition of diabetic nephropathy. The data indicates that the control of hypertension is important for inhibiting the progression of diabetic nephropathy.

Entities:  

Mesh:

Year:  1999        PMID: 10441994

Source DB:  PubMed          Journal:  Nihon Jinzo Gakkai Shi        ISSN: 0385-2385


  1 in total

Review 1.  The effect of aldosterone on glucose metabolism.

Authors:  Dalila B Corry; Michael L Tuck
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.